4.2400 +0.21 (5.21%)
Before hours: 7:04AM EST
73 High Street
Buffalo, NY 14203
United States
716 849 6810
http://www.cbiolabs.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 7
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Christopher Zosh | VP of Fin., Interim Principal Exec. Officer, Principal Financial Officer & Accounting Officer | 103.49k | N/A | 1975 |
Dr. Andrei V. Gudkov | Chief Scientific Officer | 66.14k | N/A | 1956 |
Dr. Langdon L. Miller | Chief Medical Officer | 73.72k | N/A | 1954 |
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.